U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07402044) titled 'CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)' on Dec. 18, 2025.
Brief Summary: The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.
Study Start Date: Feb. 15
Study Type: OBSERVATIONAL
Condition:
CABOTEGRAVIR
LENACAPAVIR
Recruitment St...